170 related articles for article (PubMed ID: 28370075)
1. Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias.
Kaye JA; Margulis AV; Fortuny J; McQuay LJ; Plana E; Bartsch JL; Bui CL; Perez-Gutthann S; Arana A
Pharmacotherapy; 2017 Jun; 37(6):673-683. PubMed ID: 28370075
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Common Cancers in Users of Antimuscarinic Medications for Overactive Bladder: A Danish Nationwide Cohort Study.
Hallas J; Margulis AV; Pottegård A; Kristiansen NS; Atsma WJ; Appenteng K; de Vogel S; Kaye JA; Perez-Gutthann S; Arana A
Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):612-619. PubMed ID: 29345103
[TBL] [Abstract][Full Text] [Related]
3. Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study.
Arana A; Margulis AV; McQuay LJ; Ziemiecki R; Bartsch JL; Rothman KJ; Franks B; D'Silva M; Appenteng K; Varas-Lorenzo C; Perez-Gutthann S
Pharmacotherapy; 2018 Jun; 38(6):628-637. PubMed ID: 29723926
[TBL] [Abstract][Full Text] [Related]
4. Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study.
Matta R; Gomes T; Juurlink D; Jarvi K; Herschorn S; Nam RK
Eur Urol Focus; 2022 Sep; 8(5):1433-1440. PubMed ID: 34742663
[TBL] [Abstract][Full Text] [Related]
5. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
Wagg A; Compion G; Fahey A; Siddiqui E
BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
[TBL] [Abstract][Full Text] [Related]
6. Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom.
Margulis AV; Linder M; Arana A; Pottegård A; Berglind IA; Bui CL; Kristiansen NS; Bahmanyar S; McQuay LJ; Atsma WJ; Appenteng K; D'Silva M; Perez-Gutthann S; Hallas J
PLoS One; 2018; 13(9):e0204456. PubMed ID: 30260993
[TBL] [Abstract][Full Text] [Related]
7. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
[TBL] [Abstract][Full Text] [Related]
8. A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder.
Phiri K; Hallas J; Linder M; Margulis A; Suehs B; Arana A; Bahmanyar S; Hoffman V; Enger C; Horter L; Odsbu I; Olesen M; Perez-Gutthann S; Kristiansen NS; Appenteng K; de Vogel S; Seeger J
Curr Med Res Opin; 2021 May; 37(5):867-877. PubMed ID: 33591859
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder.
Andersson KE; Sarawate C; Kahler KH; Stanley EL; Kulkarni AS
BJU Int; 2010 Jul; 106(2):268-74. PubMed ID: 19922546
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study.
Margulis AV; Hallas J; Pottegård A; Kristiansen NS; Atsma WJ; Franks B; D'Silva M; Varas-Lorenzo C; Perez-Gutthann S; Arana A
Eur J Clin Pharmacol; 2018 Feb; 74(2):193-199. PubMed ID: 29134254
[TBL] [Abstract][Full Text] [Related]
11. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
Cetinel B; Onal B; Gultekin MH; Guzelsoy M; Turegun FA; Dincer M
Int Urol Nephrol; 2019 Mar; 51(3):417-424. PubMed ID: 30725387
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.
Hoffman V; Hallas J; Linder M; Margulis AV; Suehs BT; Arana A; Phiri K; Enger C; Horter L; Odsbu I; Olesen M; Perez-Gutthann S; Xu Y; Kristiansen NS; Appenteng K; de Vogel S; Seeger JD;
Drug Saf; 2021 Aug; 44(8):899-915. PubMed ID: 34236595
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
[TBL] [Abstract][Full Text] [Related]
15. Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study.
Kachru N; Holmes HM; Johnson ML; Chen H; Aparasu RR
Curr Med Res Opin; 2021 Aug; 37(8):1303-1313. PubMed ID: 33890538
[TBL] [Abstract][Full Text] [Related]
16. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events?
Paquette A; Gou P; Tannenbaum C
J Am Geriatr Soc; 2011 Jul; 59(7):1332-9. PubMed ID: 21718264
[TBL] [Abstract][Full Text] [Related]
17. Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: a Retrospective Study.
Kachru N; Holmes HM; Johnson ML; Chen H; Aparasu RR
J Gen Intern Med; 2020 Jul; 35(7):2084-2093. PubMed ID: 32026255
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study.
Welk B; McArthur E
BJU Int; 2020 Jul; 126(1):183-190. PubMed ID: 32167223
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of neurocognitive dysfunction with overactive bladder medications.
Duong V; Iwamoto A; Pennycuff J; Kudish B; Iglesia C
Int Urogynecol J; 2021 Oct; 32(10):2693-2702. PubMed ID: 34213600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
